JPH11140102A - Apple vinegar-derived antitumoral polysaccharide and preparation thereof - Google Patents
Apple vinegar-derived antitumoral polysaccharide and preparation thereofInfo
- Publication number
- JPH11140102A JPH11140102A JP9303079A JP30307997A JPH11140102A JP H11140102 A JPH11140102 A JP H11140102A JP 9303079 A JP9303079 A JP 9303079A JP 30307997 A JP30307997 A JP 30307997A JP H11140102 A JPH11140102 A JP H11140102A
- Authority
- JP
- Japan
- Prior art keywords
- polysaccharide
- molecular weight
- linkage
- derived
- alpha
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000004676 glycans Chemical class 0.000 title claims abstract description 65
- 229920001282 polysaccharide Polymers 0.000 title claims abstract description 65
- 239000005017 polysaccharide Substances 0.000 title claims abstract description 65
- 230000000259 anti-tumor effect Effects 0.000 title claims abstract description 60
- 235000021419 vinegar Nutrition 0.000 title claims abstract description 22
- 239000000052 vinegar Substances 0.000 title claims abstract description 22
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 10
- 239000008103 glucose Substances 0.000 claims abstract description 10
- 229920002307 Dextran Polymers 0.000 claims abstract description 8
- 235000021425 apple cider vinegar Nutrition 0.000 claims description 23
- 229940088447 apple cider vinegar Drugs 0.000 claims description 23
- 239000012506 Sephacryl® Substances 0.000 claims description 10
- 238000004458 analytical method Methods 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 238000000502 dialysis Methods 0.000 claims description 5
- 238000001641 gel filtration chromatography Methods 0.000 claims description 5
- 238000002523 gelfiltration Methods 0.000 claims description 5
- 239000012528 membrane Substances 0.000 claims description 5
- 239000000872 buffer Substances 0.000 claims description 4
- 238000006243 chemical reaction Methods 0.000 claims description 4
- 239000000385 dialysis solution Substances 0.000 claims description 4
- 239000012153 distilled water Substances 0.000 claims description 4
- 230000007935 neutral effect Effects 0.000 claims description 4
- 238000004271 weak anion exchange chromatography Methods 0.000 claims description 4
- 238000005349 anion exchange Methods 0.000 claims description 3
- 238000004108 freeze drying Methods 0.000 claims description 3
- CTYRPMDGLDAWRQ-UHFFFAOYSA-N phenyl hydrogen sulfate Chemical compound OS(=O)(=O)OC1=CC=CC=C1 CTYRPMDGLDAWRQ-UHFFFAOYSA-N 0.000 claims description 3
- 230000000704 physical effect Effects 0.000 claims description 3
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 2
- 229920002271 DEAE-Sepharose Polymers 0.000 claims description 2
- 238000010521 absorption reaction Methods 0.000 claims description 2
- 239000007864 aqueous solution Substances 0.000 claims description 2
- 238000004440 column chromatography Methods 0.000 claims description 2
- 238000011033 desalting Methods 0.000 claims description 2
- 229910052740 iodine Inorganic materials 0.000 claims description 2
- 239000011630 iodine Substances 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 238000001228 spectrum Methods 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 abstract description 8
- 201000011510 cancer Diseases 0.000 abstract description 7
- 239000002994 raw material Substances 0.000 abstract description 3
- 241000220225 Malus Species 0.000 description 18
- 238000000034 method Methods 0.000 description 12
- XLYOFNOQVPJJNP-ZSJDYOACSA-N Heavy water Chemical compound [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 10
- 239000000499 gel Substances 0.000 description 7
- 238000000926 separation method Methods 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 239000002504 physiological saline solution Substances 0.000 description 6
- 230000004083 survival effect Effects 0.000 description 6
- 229920001503 Glucan Polymers 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 238000005576 amination reaction Methods 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 229920002527 Glycogen Polymers 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 238000005481 NMR spectroscopy Methods 0.000 description 3
- 230000000118 anti-neoplastic effect Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 229940096919 glycogen Drugs 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 3
- 125000004076 pyridyl group Chemical group 0.000 description 3
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 240000007594 Oryza sativa Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- 235000021016 apples Nutrition 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- 235000015170 shellfish Nutrition 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 229920000310 Alpha glucan Polymers 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 244000131316 Panax pseudoginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229940095714 cider vinegar Drugs 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 238000005227 gel permeation chromatography Methods 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 230000008076 immune mechanism Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 210000003200 peritoneal cavity Anatomy 0.000 description 1
- 201000002628 peritoneum cancer Diseases 0.000 description 1
- OQUKIQWCVTZJAF-UHFFFAOYSA-N phenol;sulfuric acid Chemical compound OS(O)(=O)=O.OC1=CC=CC=C1 OQUKIQWCVTZJAF-UHFFFAOYSA-N 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000010421 standard material Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- WUUHFRRPHJEEKV-UHFFFAOYSA-N tripotassium borate Chemical compound [K+].[K+].[K+].[O-]B([O-])[O-] WUUHFRRPHJEEKV-UHFFFAOYSA-N 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 239000012610 weak anion exchange resin Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Abstract
Description
【0001】[0001]
【発明の目的】この発明は、抗腫瘍性多糖に関するもの
であって、特に青森県特産のリンゴから醸造されたリン
ゴ酢を原料にして抽出、精製して得られるところの抗腫
瘍活性を示す新規な構造からなるリンゴ酢由来抗腫瘍性
多糖を提供しようとするものである。The present invention relates to an antitumor polysaccharide, and more particularly to a novel antitumor activity obtained by extracting and purifying apple vinegar brewed from apples specially produced in Aomori Prefecture. An object of the present invention is to provide an apple vinegar-derived antitumor polysaccharide having a simple structure.
【0002】[0002]
【従来の技術】北米バーモント地方の人々が好んで飲用
しているバーモント酢、即ち、ティースプーン1杯のリ
ンゴ酢に同じく1杯の蜂蜜を加え、コップ一杯の水で薄
めた飲み物は、バーモント地方の人々が長寿を保てる理
由の一つと考えられていて、非常に健康に良いものとい
われてきているが、その効果を示す生理活性物質の構造
的知見ついて、これまでのところ開示されたという情報
は全くなく、先の事実からして、全国一のリンゴ生産を
誇る特異な地域柄から、その解明は極めて興味深いテー
マの一つとなっていた。BACKGROUND OF THE INVENTION Vermont vinegar, a favorite of the people of the Vermont region of North America, is a drink prepared by adding a teaspoon of apple cider vinegar to a cup of honey and diluting with a glass of water. Is considered to be one of the reasons why people can maintain longevity, and it is said that it is very good for health, but information on the structural knowledge of bioactive substances showing the effect has been disclosed so far According to the above fact, it was one of the most interesting themes because of the unique region that boasts the best apple production in the whole country.
【0003】現代社会において長寿を全うできる条件と
しては様々な要因を考慮しなければならいが、その中で
も、悪性腫瘍(癌)への罷病率の多寡は、長寿の条件を
判断する上で重要な因子となり得ることが既に周知され
ている。Various factors must be considered as conditions for achieving longevity in modern society. Among them, the rate of malignant tumors (cancer) is important in judging the conditions for longevity. It is already well known that this can be a factor.
【0004】一方、これまでにも、数多くの宿主仲介性
の抗腫瘍性多糖が、穀類や果実等といった種々の材料か
ら見い出されているのも事実であり、例えば、キノコ等
から抽出されたβ−(1,3)(1,6)−グルカンは
非常に有名であり、更に、各糖残基間のグルコシド結合
がアルファ結合をとっている抗腫瘍性多糖のその他の例
としは、例えば、昭和61年特許公開第18722号公
報に掲載された発明に見られるように、米糠を原料とし
たアルファ−(1,6)−グルカンがあり、また、人参
三七の根から得られるアルファ−(1,4)−グルカン
は、平成1年特許公開第88688号公報の発明として
掲載されており、また、平成6年特許公開第27929
号公報には、貝類を原料としたグリコーゲン、アルファ
−(1,4)(1,6)−グルカンが、分子量10万以
上の抗腫瘍性多糖として掲載されている。[0004] On the other hand, it is a fact that many host-mediated antineoplastic polysaccharides have been found from various materials such as cereals and fruits. For example, β-cells extracted from mushrooms and the like have been found. -(1,3) (1,6) -glucan is very famous, and further examples of antitumor polysaccharides in which the glucosidic bond between each sugar residue has an alpha bond include, for example: As can be seen from the invention disclosed in Japanese Patent Publication No. 18722/1986, there is alpha- (1,6) -glucan using rice bran as a raw material, and alpha- ( 1,4) -Glucan is described as an invention in Japanese Patent Publication No. 88688/1999, and in Japanese Patent Publication No. 27929/1994.
In this publication, glycogen and alpha- (1,4) (1,6) -glucan using shellfish as a raw material are described as antitumor polysaccharides having a molecular weight of 100,000 or more.
【0005】これらのことを類推、勘案した結果、北米
バーモント地方の人々の長寿の要因の一つと考えられて
いるリンゴ酢が、何かある種の抗腫瘍性多糖を含んでい
るのではないかとの予測をたて、この発明では、リンゴ
酢から抗腫瘍性を有する新規な多糖成分を見い出すべ
く、逸早く、慎重な分析、検討を加えてきたところ、遂
に、以下において詳述するとおりの新規な構造からなる
りんご酢由来抗腫瘍性多糖と、それを抽出、精製するた
めの新規な製造方法とを完成、実用化することに成功し
たものである。[0005] As a result of analogy and consideration of these facts, apple vinegar, which is considered to be one of the causes of longevity in the people of Vermont, North America, may contain some kind of antitumor polysaccharide. According to the present invention, in order to find a novel antitumor polysaccharide component from apple vinegar, the present invention has been promptly and carefully analyzed and examined, and finally a novel polysaccharide component as described in detail below. An apple tumor vinegar-derived antitumor polysaccharide having a structure and a novel production method for extracting and purifying it have been successfully completed and put to practical use.
【0006】[0006]
【発明の構成】この発明のリンゴ酢由来抗腫瘍性多糖
は、基本的に以下のとおりの構成を要件とするものであ
る。即ち アルファ−1,4−結合の主鎖にアルファ−
1,6−結合の分岐構造を有するグルコースを主成分と
し、分子量範囲が、デキストラン換算で7000以上1
7000以下、平均分子量略10000のリンゴ酢由来
抗腫瘍性多糖である。The antitumor polysaccharide derived from apple cider vinegar of the present invention basically requires the following constitution. In other words, the main chain of alpha-1,4-linkage contains alpha-
The main component is glucose having a 1,6-bonded branched structure, and the molecular weight range is from 7000 to 1 in terms of dextran.
It is an antitumor polysaccharide derived from apple cider vinegar having an average molecular weight of about 10,000 or less.
【0007】上記のとおりの構造を基本とするこの発明
のリンゴ酢由来抗腫瘍性多糖は、物性からその構成を示
せば、 (a) 分子量範囲がデキストラン換算で7000
以上17000以下であり、セファクリル S−300
によるゲル濾過分析によって平均分子量10000に主
ピークを有すること。 (b) グルコースを主成分とする
多糖であること。 (c) 分子内にアルファ−1,4−結
合およびアルファ−1,6−結合を有すること。以上の
とおりの、少なくとも3要素を備えてなることを特徴を
有するリンゴ酢由来抗腫瘍性多糖と言うことができる。The antitumor polysaccharide derived from apple cider vinegar of the present invention having the above-described structure as a basic structure has the following properties: (a) a molecular weight range of 7000 in terms of dextran;
Not less than 17000 and Sephacryl S-300
Has a main peak at an average molecular weight of 10,000 by gel filtration analysis according to the above. (b) Be a polysaccharide containing glucose as a main component. (c) having an alpha-1,4-linkage and an alpha-1,6-linkage in the molecule; As described above, the antitumor polysaccharide derived from apple cider vinegar is characterized by having at least three components.
【0008】更に具体的には、次のとおりの物性を特徴
とするリンゴ酢由来抗腫瘍性多糖であるとしてその構成
を示すことも可能である。即ち、(a) 白色ないし淡褐色
粉末で、水に溶けやすいこと。 (b) 分子量範囲が、デ
キストラン換算で7000以上17000以下であり、
セファクリルS−300によるゲル濾過分析によって平
均分子量10000に主ピークを有していること。
(c) グルコースを主成分とする多糖であること。 (d)
プロトン−NMR(Nuclear Magnetic
Resonance)スペクトルを示し、NMRによ
って糖のみからなるシグナルを示すこと。 (e) 透析膜
を通過しないこと。 (f) フェノール硫酸反応で陽性、
ヨード反応で陽性を示すこと。 (g) 水溶液中における
紫外部吸収極大を示さないこと。 (h) 分子内にアルフ
ァ−1,4−結合およびアルファ−1,6−結合を有し
ていること。の8要素を備えてなるリンゴ酢由来抗腫瘍
性多糖である。[0008] More specifically, it is also possible to show the composition as an antitumor polysaccharide derived from apple cider vinegar, which has the following physical properties. That is, (a) a white or light brown powder that is easily soluble in water. (b) the molecular weight range is from 7000 to 17000 in dextran equivalent,
It has a main peak at an average molecular weight of 10,000 by gel filtration analysis using Sephacryl S-300.
(c) A polysaccharide containing glucose as a main component. (d)
Proton-NMR (Nuclear Magnetic)
(Resonance) spectrum, and a signal consisting only of sugar by NMR. (e) Do not pass through the dialysis membrane. (f) Positive in phenol sulfate reaction,
Show positive in iodine reaction. (g) Must not exhibit an ultraviolet absorption maximum in an aqueous solution. (h) having an alpha-1,4-linkage and an alpha-1,6-linkage in the molecule; Is an antitumor polysaccharide derived from apple cider vinegar comprising the following eight elements:
【0009】[0009]
【関連する発明】この発明には、上記したリンゴ酢由来
抗腫瘍性多糖に関連し、以下のとおりの構成からなるリ
ンゴ酢由来抗腫瘍性多糖の製造方法を包含している。先
ず、リンゴ酢を減圧濃縮後あるいはそのまま蒸留水に対
して透析(例えば、三光純薬株式会社、透析膜36/3
2、分子量12000〜14000等)を行い、透析内
液を凍結乾燥する工程。次いで、上記凍結乾燥物をセフ
ァクリル S−300ゲルによるゲルロ過クロマトグラ
フィーを行い、デキストラン換算で1000以上400
00以下の画分を得た上、脱塩する工程。その後におい
て、弱陰イオン交換クロマトグラフィー、例えばDEA
E セファロース ファースト フロー陰イオン交換ゲ
ル(商品名、ファルマシア社製等)を充填したカラムク
ロマトグラフィーに付し、カラム担体容量の少なくとも
2倍量の希薄な中性緩衝液で溶出脱塩後、凍結乾燥する
工程。以上の工程からなるリンゴ酢由来抗腫瘍性多糖の
製造方法である。[Related Invention] The present invention relates to the above-mentioned anti-tumor polysaccharide derived from apple cider vinegar and includes a method for producing an anti-tumor polysaccharide derived from apple cider vinegar having the following constitution. First, apple vinegar is concentrated under reduced pressure or dialyzed directly against distilled water (for example, Sanko Junyaku Co., Ltd., Dialysis membrane 36/3).
2, a molecular weight of 12000 to 14000) and freeze-drying the dialysis solution. Next, the freeze-dried product was subjected to gel permeation chromatography using Sephacryl S-300 gel, and it was 1000 to 400 in terms of dextran.
A step of obtaining a fraction of 00 or less and then desalting. Thereafter, weak anion exchange chromatography, such as DEA
E Sepharose Fast flow Anion exchange gel (trade name, manufactured by Pharmacia, etc.) was applied to column chromatography, eluted with a dilute neutral buffer at least twice the volume of the column carrier, desalted, and then lyophilized. Process. This is a method for producing an antitumor polysaccharide derived from apple vinegar, comprising the above steps.
【0010】上記透析、ゲル濾過クロマトグラフィー、
弱陰イオン交換クロマトグラフィー等においては、他の
ゲル濾過担体、イオン交換樹脂、限外濾過膜等を用いて
行うことができる。The above dialysis, gel filtration chromatography,
In weak anion exchange chromatography or the like, it can be performed using another gel filtration carrier, an ion exchange resin, an ultrafiltration membrane or the like.
【0011】この発明の方法によって抽出分離精製され
た抗腫瘍性多糖の性質は、化学分析結果から、次のとお
りである。 「平均分子量」図2のセファクリル S−200ゲル
(商品名、ファルマシア社製)濾過クロマトグラフィー
による流出パターンから、標準資料の流出液量に対する
それら分子量の片対数プロットに抗腫瘍性多糖の流出液
量を外挿することにより、分子量を推定したところ、リ
ンゴ酢由来抗腫瘍性多糖の平均分子量10000である
ことが判明した。The properties of the antitumor polysaccharide extracted and purified by the method of the present invention are as follows from the results of chemical analysis. "Average molecular weight" From the effluent pattern by Sephacryl S-200 gel (trade name, manufactured by Pharmacia) filtration chromatography in FIG. 2, the semi-log plot of those molecular weights with respect to the effluent amount of the standard material shows the effluent amount of the antitumor polysaccharide. Was extrapolated to find that the molecular weight was estimated, and the average molecular weight of the antitumor polysaccharide derived from apple cider vinegar was 10,000.
【0012】「プロトンNMR」この化学分析は、乾燥
資料2ミリグラムを99.8%D2Oに溶解し、12時
間室温で振盪し、重水置換を行い、凍結乾燥した。同様
の操作を99.8%D2Oおよび99.95%D2Oに
て行い、次に99.93%D2Oに溶解し、70°Cで
NMRを測定した。NMRの測定には、270−MHZ
1H−NMR(JNM EX−270、日本電気製)を
使用した。その結果が、図1のとおりであって、5.3
73ppmにα−1,4結合に由来するシグナル、4.
963ppmにα−1,4,6結合に由来するシグナル
を示し、3.4−4.4ppmに多糖由来と思われるシ
グナルが捕らえられ、糖のみからなるシグナルを示す。"Proton NMR" In this chemical analysis, 2 milligrams of the dried material was dissolved in 99.8% D2O, shaken at room temperature for 12 hours, replaced with heavy water, and freeze-dried. The same operation was performed with 99.8% D2O and 99.95% D2O, and then dissolved in 99.93% D2O, and NMR was measured at 70 ° C. For NMR measurement, 270-MHZ
1H-NMR (JNM EX-270, manufactured by NEC) was used. The result is as shown in FIG.
3. a signal derived from α-1,4 bond at 73 ppm;
At 963 ppm, a signal derived from α-1,4,6 bond is shown, and at 3.4-4.4 ppm, a signal thought to be derived from polysaccharide is captured, and a signal consisting of only saccharide is shown.
【0013】「化学成分分析値」糖の組織組成が、次の
分析法によってグルコースのみからなることが判明す
る。即ち、2規定塩酸で2時間加水分解したものをサン
プルとし、ピリジルアミノ化装置(宝酒造株式会社 P
ALSTATION model 4000)でピリジ
ルアミノ化したものを PALPAK TypeAカラ
ム(4.6×150mm)を用い、溶媒は、0.7M
カリウム−ホウ酸 緩衝液(pH9.0)/アセトニト
リル(90/10,v/v)、流速は、0.3ミリリッ
トル/分、カラム温度は65℃、検出は蛍光検出器を用
い励起波長310nm測定波長380nmで、HPLC
(High peformace Liquid Ch
romatography)による糖組成分析した結
果、図3のリンゴ酢由来抗腫瘍性多糖のピリジルアミノ
化法による糖組成分析による分離パターンが示している
ように、リンゴ酢由来抗腫瘍性多糖は、キシロール、グ
ルコース、マンノースおよびガラクトースからなる多糖
であり、その殆どがグルコース(9.7%)からなる多
糖であることが明らかにされた。以下では、この発明に
おける抗腫瘍性多糖の製造法、および、有効画分の投与
法の例を、更に詳しく説明することにする。"Chemical component analysis value" It is found that the tissue composition of sugar is composed only of glucose by the following analysis method. That is, a sample obtained by hydrolyzing with 2N hydrochloric acid for 2 hours is used as a sample, and a pyridyl amination apparatus (Takara Shuzo Co., Ltd.
Using a PALPAK Type A column (4.6 × 150 mm) obtained by apyridyl amination using ALSTATION model 4000), the solvent was 0.7 M
Potassium-borate buffer (pH 9.0) / acetonitrile (90/10, v / v), flow rate: 0.3 ml / min, column temperature: 65 ° C., detection: measurement of excitation wavelength 310 nm using a fluorescence detector HPLC at wavelength 380nm
(High performance Liquid Ch
As a result of the sugar composition analysis by romatography, as shown in FIG. 3, the separation pattern of the apple vinegar-derived anti-tumor polysaccharide by the pyridyl amination method of the apple vinegar-derived anti-tumor polysaccharide is shown as xylol, glucose, It was revealed that the polysaccharide was composed of mannose and galactose, most of which was composed of glucose (9.7%). Hereinafter, an example of the method for producing an antitumor polysaccharide and the method for administering an effective fraction in the present invention will be described in more detail.
【0014】[0014]
【実施例1】この実施例は、リンゴ酢からの抗腫瘍性多
糖の抽出方法の一事例を示すものであり、リンゴ酢50
0ミリリットルを100ミリリットルに減圧濃縮後、蒸
留水70ミリリットルを加えて全量170ミリリットル
にした後、再び減圧濃縮し、凡そ全量100ミリリット
ルにしたものを、蒸留水に対して透析した。透析内液
(粗抗腫瘍性多糖)は、凍結乾燥後、冷蔵保存した。な
お、透析内液の乾燥重量は、りんご酢乾燥重量の約7%
であった。EXAMPLE 1 This example shows one example of a method for extracting an antitumor polysaccharide from apple cider vinegar.
After 0 ml was concentrated under reduced pressure to 100 ml, 70 ml of distilled water was added to make the total amount 170 ml, and the mixture was concentrated again under reduced pressure to give a total amount of approximately 100 ml, and dialyzed against distilled water. The dialysis solution (crude antitumor polysaccharide) was lyophilized and stored refrigerated. The dry weight of the dialysis solution is about 7% of the apple cider vinegar dry weight.
Met.
【0015】[0015]
【実施例2】次に、分離、精製例を示すと、粗抗腫瘍性
多糖20ミリグラムを0.1モル塩化ナトリウム水溶液
に溶解し、セファクリル S−300ゲル(商品名、フ
ァルマシア社製)、カラム(2.3×118cm)によ
り、溶出液として0.1モルNaClを用い、流速は、
0.5ミリリットル/分で精製した。各フラクション
(5ミリリットル)をフェノール硫酸法で中性糖を測定
し、流出パターンを図4に示してある。F1、F2およ
びF3の三つの画分に分け、脱塩後,凍結乾燥した。収
量は、F1が1.6ミリグラム(12.8%)、F2が
3.8ミリグラム(30.4%),およびF3が7.0
ミリグラム(56.8%)であった。EXAMPLE 2 Next, as an example of separation and purification, 20 mg of a crude antitumor polysaccharide was dissolved in an aqueous 0.1 M sodium chloride solution, and Sephacryl S-300 gel (trade name, manufactured by Pharmacia), column (2.3 × 118 cm), 0.1 M NaCl was used as the eluate, and the flow rate was
Purified at 0.5 ml / min. Neutral sugar was measured for each fraction (5 ml) by the phenol-sulfuric acid method, and the outflow pattern is shown in FIG. It was divided into three fractions F1, F2 and F3, desalted, and lyophilized. The yields were 1.6 mg (12.8%) for F1, 3.8 mg (30.4%) for F2, and 7.0 for F3.
Milligrams (56.8%).
【0016】更に、このF3を、DEAE セファロー
ス ファースト フロー陰イオン交換ゲル(商品名、フ
ァルマシア社製)を用いた弱陰イオン交換クロマトグラ
フィーによって分画精製した。溶出緩衝液には20ミリ
モル/リットル トリス−塩酸緩衝液(pH7.2)を
用い、分離した(図3を参照)。フェノール硫酸法で中
性糖を測定し、3つの画分(a・b・c)に分け、透析
後、凍結乾燥した。収量は、aが3.6ミリグラム(5
6%) 、bが1.7ミリグラム(25%)、およびc
1.2ミリグラム(19%)であった。図中、aがりん
ご酢由来抗腫瘍性多糖である。Further, this F3 was fractionated and purified by weak anion exchange chromatography using DEAE Sepharose Fast Flow anion exchange gel (trade name, manufactured by Pharmacia). Separation was performed using 20 mmol / liter Tris-HCl buffer (pH 7.2) as an elution buffer (see FIG. 3). Neutral sugar was measured by the phenol sulfate method, divided into three fractions (abc), dialyzed, and lyophilized. The yield was 3.6 mg of a (5 mg).
6%), b is 1.7 milligrams (25%), and c
1.2 milligrams (19%). In the figure, a is apple cider vinegar-derived antitumor polysaccharide.
【0017】[0017]
【実施例3】抗腫瘍実験例は、次のとおりである。6週
令メス、平均体重20グラムのBALB/C−CRJマ
ウスに1週間、同系のマウスの腹腔内で継代した癌細胞
Meth−Aを、マウス1匹当たり1×105個を腹腔
内に移植し、対照群5匹(1群)と試験群(1群)の計
2群に分けた。Example 3 An example of an antitumor experiment is as follows. A 6-week-old female, BALB / C-CRJ mouse weighing an average of 20 grams was transplanted with 1 x 105 peritoneal peritoneal cancer cells Meth-A, which had been passaged intraperitoneally to syngeneic mice for 1 week. The test group (1 group) and the test group (1 group) were divided into two groups.
【0018】癌細胞を移植した2日目、4日目、6日目
に、試験群には、0.625ミリグラムの抗腫瘍性多糖
を0.2ミリリットルの生理食塩水に溶解し、腹腔内に
投与した。対照群には、同様にして生理食塩水のみを投
与した。以後、生存日数を60日まで観察し、延命効果
を次式によって算出した。 延命率(%)=(試験群の平均生存日数群)/(対照群
の平均生存日数)×100 上記方法によって検定したリンゴ酢由来抗腫瘍性多糖の
抗腫瘍効果は、下表のとおりであった。On the second, fourth, and sixth days after the transplantation of the cancer cells, the test group was prepared by dissolving 0.625 milligrams of the antitumor polysaccharide in 0.2 milliliter of physiological saline and intraperitoneally. Was administered. The control group was similarly administered only with physiological saline. Thereafter, the number of surviving days was observed up to 60 days, and the survival effect was calculated by the following equation. Survival rate (%) = (average surviving days of test group) / (average surviving days of control group) × 100 The antitumor effect of the antitumor polysaccharide derived from apple cider vinegar, which was tested by the above method, is as shown in the table below. Was.
【0019】[0019]
【表1】 [Table 1]
【0020】[0020]
【実施例4】続いて、第2の抗腫瘍実験例を示すと、次
のとおりである。6週令メス、平均体重20グラムのB
ALB/C−CRJマウスに1週間、同系のマウスの腹
腔内で継代した癌細胞Meth−Aを、マウス1匹当た
り1×105個を腹腔内に移植し、対照群5匹(1群)
と試験群(1群)の計2群に分けた。Embodiment 4 Next, a second example of an antitumor experiment will be described. 6 week old female, average weight 20g B
ALB / C-CRJ mice were intraperitoneally transplanted with 1 × 10 5 cancer cells Meth-A per mouse intraperitoneally for 1 week, and 5 control mice (1 group)
And a test group (1 group).
【0021】癌細胞を移植した2日目、4日目、6日目
に、試験群には、0.2ミリグラムの抗腫瘍性多糖を
0.2ミリリットルの生理食塩水に溶解し、腹腔内に投
与した。対照群には、同様にして生理食塩水のみを投与
した。以後、生存日数を60日まで観察し、延命効果を
次式によって算出した。延命率(%)=(試験群の平均
生存日数群)/(対照群の平均生存日数)×100上記
方法によって検定したリンゴ酢由来抗腫瘍性多糖の抗腫
瘍効果を示すと、下表のとおりでる。On the second, fourth, and sixth days after the transplantation of the cancer cells, the test group was prepared by dissolving 0.2 mg of the antitumor polysaccharide in 0.2 ml of physiological saline and intraperitoneally. Was administered. The control group was similarly administered only with physiological saline. Thereafter, the number of surviving days was observed up to 60 days, and the survival effect was calculated by the following equation. Survival rate (%) = (average survival days of test group) / (average survival days of control group) × 100 The antitumor effect of apple cider vinegar-derived antitumor polysaccharide tested by the above method is shown in the table below. Out.
【0022】[0022]
【表2】 [Table 2]
【0023】[0023]
【作用効果】リンゴ酢由来抗腫瘍性多糖を用いた腫瘍に
対する治療法としては、リンゴ酢由来抗腫瘍性多糖を生
理食塩水、あるいは各種塩溶液に溶解の後、病巣部に直
接注射による投与、静脈投与等が可能である。また、本
来生体内に存在する物質と似ているため、毒性は無く、
したがって、その病状により、その投与量を広い範囲で
コントロールし得る。[Effects] As a treatment method for a tumor using an apple vinegar-derived anti-tumor polysaccharide, the apple vinegar-derived anti-tumor polysaccharide is dissolved in physiological saline or various salt solutions, and then administered directly to a lesion by direct injection. Intravenous administration is possible. In addition, because it is similar to substances that exist in the body, there is no toxicity,
Thus, the dosage can be controlled over a wide range depending on the condition.
【0024】この発明において、その抗腫瘍活性を以下
の方法によって確認することができる。即ち、マウスの
腹腔内に腫瘍細胞を移植し、このマウスにリンゴ酢由来
抗腫瘍性多糖を生理食塩水に溶解させ、投与することに
よって腫瘍を治癒することができた。この実験におい
て、治癒されたマウスに副作用は観察されなかったこと
にから、急性毒性はないものと考えられ、腫瘍に対し大
変有望な物質であることを確認することができた。In the present invention, its antitumor activity can be confirmed by the following method. That is, tumor cells could be cured by implanting tumor cells into the peritoneal cavity of a mouse, dissolving the apple vinegar-derived antitumor polysaccharide in physiological saline, and administering the solution. In this experiment, since no side effects were observed in the cured mice, it was considered that there was no acute toxicity, and it was confirmed that the mice were very promising substances for tumors.
【0025】このような特徴を有する抗腫瘍性多糖とし
ては、キノコ等から抽出されたβ−(1,3)(1,
6)−グルカンが有名であるが、この発明におけるリン
ゴ酢由来抗腫瘍性多糖は、各糖鎖残基間のグリコシド結
合が逆のアルファ結合をとっており、物質的に全く異な
るものである。また、抗腫瘍性活性を示す多糖には、こ
の他にも幾つか存在することが報告されており、これら
多糖のアルファ−グルカンで抗腫瘍性のあるものも知ら
れているが、それらはアルファ−1,4−結合のみから
なるもの(人参三七の根から得られる多糖等)、あるい
はアルファ−1,6−結合のみからなるもの(米糠を原
料とした多糖等)であって、この発明のリンゴ酢由来抗
腫瘍性多糖とは、その構造および分子量が大きく異な
る。Antitumor polysaccharides having such characteristics include β- (1,3) (1,1) extracted from mushrooms and the like.
6) -Glucan is famous, but the antitumor polysaccharide derived from apple cider vinegar in the present invention is a material which is completely different in that glycoside bonds between the sugar chain residues take reverse alpha bonds. In addition, it has been reported that there are several other polysaccharides exhibiting antineoplastic activity, and there are known alpha-glucans of these polysaccharides which have antineoplastic properties. The present invention relates to a product comprising only -1,4-linkage (polysaccharide obtained from the roots of ginseng 37) or a product comprising only alpha-1,6-linkage (polysaccharide derived from rice bran). Is significantly different from the apple vinegar-derived antitumor polysaccharide in its structure and molecular weight.
【0026】また、アルファ−1,4−結合とアルファ
−1,6−結合とを持つグリコーゲン(貝類を原料とし
たグリコーゲン等)も知られているが、この発明のリン
ゴ酢由来抗腫瘍性多糖の分子量が2万以下であるのに対
し、それら公知のものは、分子量10万以上であって全
く別の物質である。Glycogen having an alpha-1,4-linkage and an alpha-1,6-linkage (eg, a glycogen obtained from shellfish) is also known, but the antitumor polysaccharide derived from apple cider vinegar of the present invention is also known. Has a molecular weight of 20,000 or less, whereas those known are completely different substances having a molecular weight of 100,000 or more.
【0027】叙述の如く、この発明は、通常食されてい
るリンゴ酢から抗腫瘍多糖を抽出し、且つその得られた
抗腫瘍多糖の抗腫瘍活性に関する開発、研究を継続し、
幾多の試行錯誤を重ねてきた結果、遂にこの発明のリン
ゴ酢由来抗腫瘍多糖には、強い抗腫瘍性があることを確
認することに成功し得たものであり、この固有の特徴
は、この発明のリンゴ酢由来抗腫瘍多糖に細胞毒性が見
られないことにより、免疫機構、つまり、生体の本来持
つべき自己防御機構を活性化して腫瘍細胞に対する抵抗
性を高め、その結果、腫瘍細胞の増殖を抑制するのでは
ないかと考えられるものであり、この有効な特徴によ
り、この地域の特産となっているリンゴが、大いにその
付加価値を高めた活用を可能として地域産業の発展に寄
与できると共に、何よりも人類医学の面で高い評価が得
られるものと予想される。As described above, the present invention continues to develop and study the extraction of antitumor polysaccharide from normally eaten apple vinegar, and the antitumor activity of the obtained antitumor polysaccharide.
As a result of repeated trial and error, it was finally possible to confirm that the cider vinegar-derived antitumor polysaccharide of the present invention has strong antitumor properties. The absence of cytotoxicity in the anti-tumor polysaccharide derived from apple cider vinegar of the present invention activates the immune mechanism, that is, the self-defense mechanism that the living body should have, thereby increasing the resistance to tumor cells. As a result, the proliferation of tumor cells With this effective feature, apples that have become a specialty of the region can be used with greatly increased added value and contribute to the development of local industries, It is expected that a high reputation in human medicine will be obtained above all.
【図1】リンゴ酢由来抗腫瘍多糖のプロトン−NMRス
ペクトルである。FIG. 1 is a proton-NMR spectrum of an antitumor polysaccharide derived from apple vinegar.
【図2】粗抗腫瘍多糖のセファクリル S−300 ゲ
ルによるゲル濾過クロマトグラフィー分離パターンであ
る。FIG. 2 is a gel filtration chromatography separation pattern of crude anti-tumor polysaccharide on Sephacryl S-300 gel.
【図3】リンゴ酢由来抗腫瘍性多糖のピリジルアミノ化
法による糖組成分析による分離パターンである。FIG. 3 is a separation pattern obtained by analyzing a sugar composition of an antitumor polysaccharide derived from apple cider vinegar by a pyridyl amination method.
【図4】リンゴ酢由来抗腫瘍多糖のセファクリル S−
200 ゲルによるゲル濾過クロマトグラフィー分離パ
ターンである。FIG. 4. Sephacryl S-, an antitumor polysaccharide derived from apple cider vinegar
200 is a gel filtration chromatography separation pattern using 200 gels.
【図5】ゲル濾過クロマトグラフィーF3画分のDEA
E セファロース ファースト フロー 弱陰イオン交
換樹脂によるイオン交換クロマトグラフィー分離パター
ンである。FIG. 5. DEA of F3 fraction of gel filtration chromatography
E Sepharose Fast Flow It is an ion exchange chromatography separation pattern by a weak anion exchange resin.
───────────────────────────────────────────────────── フロントページの続き (72)発明者 櫛引 利貞 青森県弘前市蔵主町15番地23号 カネショ ウ株式会社内 (72)発明者 荒井 吏香子 青森県南津軽郡尾上町大字日沼字富田30の 9 弘前機能性食品開発協同組合内 ──────────────────────────────────────────────────続 き Continued on the front page (72) Inventor Toshisada Kushibiki 15-23, Kurashimachi, Hirosaki City, Aomori Prefecture Inside Kanesho Co., Ltd. (72) Inventor Rikako Arai 9 Hirosaki Functional Food Development Cooperative
Claims (4)
ァ−1,6−結合の分岐構造を有するグルコースを主成
分とし、分子量範囲が、デキストラン換算で7000以
上17000以下、平均分子量略10000のリンゴ酢
由来抗腫瘍性多糖。The present invention comprises glucose having a branched structure of alpha-1,6-linkage in the main chain of alpha-1,4-linkage as a main component, a molecular weight range of 7000 to 17000 in dextran equivalent, and an average molecular weight of about 10,000. Apple vinegar-derived antitumor polysaccharide.
ンゴ酢由来抗腫瘍性多糖。 (a) 分子量範囲がデキストラン換算で7000以上1
7000以下であり、セファクリル S−300による
ゲル濾過分析によって平均分子量10000に主ピーク
を有すること。 (b) グルコースを主成分とする多糖であること。 (c) 分子内にアルファ−1,4−結合およびアルファ
−1,6−結合を有すること。2. An antitumor polysaccharide derived from apple cider vinegar, having the following physical properties. (a) The molecular weight range is 7000 or more in terms of dextran and 1
7000 or less and having a main peak at an average molecular weight of 10,000 by gel filtration analysis with Sephacryl S-300. (b) Be a polysaccharide containing glucose as a main component. (c) having an alpha-1,4-linkage and an alpha-1,6-linkage in the molecule;
ンゴ酢由来抗腫瘍性多糖。 (a) 白色ないし淡褐色粉末で、水に溶けやすいこと。 (b) 分子量範囲がデキストラン換算で7000以上1
7000以下であり、セファクリル S−300による
ゲル濾過分析によって平均分子量10000に主ピーク
を有すること。 (c) グルコースを主成分とする多糖であること。 (d) プロトン−Nuclear Magnetic
Resonance(NMR)スペクトルを示し、NM
Rによって糖のみからなるシグナルを示すこと。 (e) 透析膜を通過しないこと。 (f) フェノール硫酸反応およびヨード反応で、夫々陽
性を示すこと。 (g) 水溶液中における紫外部吸収極大を示さないこ
と。 (h) 分子内にアルファ−1,4−結合およびアルファ
−1,6−結合を有すること。3. An antitumor polysaccharide derived from apple cider vinegar, having the following physical properties. (a) White or light brown powder that is easily soluble in water. (b) The molecular weight range is 7000 or more in terms of dextran and 1
7000 or less and having a main peak at an average molecular weight of 10,000 by gel filtration analysis with Sephacryl S-300. (c) A polysaccharide containing glucose as a main component. (d) Proton-Nuclear Magnetic
4 shows a Resonance (NMR) spectrum, NM
R indicates a signal consisting only of sugar. (e) Do not pass through the dialysis membrane. (f) Positive in phenol sulfate reaction and iodine reaction respectively. (g) Must not exhibit an ultraviolet absorption maximum in an aqueous solution. (h) having an alpha-1,4-linkage and an alpha-1,6-linkage in the molecule;
蒸留水に対して透析(透析膜36/32、分子量120
00〜14000)を行い、透析内液を凍結乾燥する工
程、 上記凍結乾燥物をセファクリル S−300ゲル
によるゲルロ過クロマトグラフィーを行い、デキストラ
ン換算で1000以上40000以下の画分を得て脱塩
する工程、 および、その後、弱陰イオン交換クロマト
グラフィー、例えばDEAE セファロース ファース
ト フロー陰イオン交換ゲルを充填したカラムクロマト
グラフィーに付し、カラム担体容量の少なくとも2倍量
の希薄な中性緩衝液で溶出、脱塩した後、凍結乾燥する
工程、からなるリンゴ酢由来抗腫瘍性多糖の製造法。4. Apple apple vinegar is concentrated under reduced pressure or dialyzed against distilled water (dialysis membrane 36/32, molecular weight 120).
00-14000) and freeze-drying the dialysis solution. The freeze-dried product is subjected to gel filtration chromatography using Sephacryl S-300 gel to obtain a dextran-equivalent fraction of 1,000 to 40,000 and desalted. And then subjected to weak anion exchange chromatography, for example column chromatography packed with DEAE Sepharose Fast Flow anion exchange gel, eluting with at least twice the volume of the column carrier in dilute neutral buffer, A method for producing an antitumor polysaccharide derived from apple cider vinegar, comprising the steps of desalting and freeze-drying.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP30307997A JP4820956B2 (en) | 1997-11-05 | 1997-11-05 | Method for producing apple vinegar-derived antitumor polysaccharide and apple vinegar-derived antitumor polysaccharide obtained thereby |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP30307997A JP4820956B2 (en) | 1997-11-05 | 1997-11-05 | Method for producing apple vinegar-derived antitumor polysaccharide and apple vinegar-derived antitumor polysaccharide obtained thereby |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH11140102A true JPH11140102A (en) | 1999-05-25 |
| JP4820956B2 JP4820956B2 (en) | 2011-11-24 |
Family
ID=17916649
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP30307997A Expired - Fee Related JP4820956B2 (en) | 1997-11-05 | 1997-11-05 | Method for producing apple vinegar-derived antitumor polysaccharide and apple vinegar-derived antitumor polysaccharide obtained thereby |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP4820956B2 (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7201924B2 (en) * | 2001-09-07 | 2007-04-10 | Peter Grandics | Method for cancer therapy using herbal extracts |
| EP1539202A4 (en) * | 2002-08-23 | 2008-01-09 | Sterogene Bioseparations Inc | METHOD OF TREATING CANCER USING HERB EXTRACTS |
| CN104877037A (en) * | 2015-05-21 | 2015-09-02 | 北京电子科技职业学院 | Separation and purification method, products and application of Christia vespertilionis polysaccharides |
| US10233264B2 (en) * | 2016-05-04 | 2019-03-19 | South China Botanical Garden, Chinese Academy Of Sciences | Process for preparing (1→6)-α-D-glucan |
-
1997
- 1997-11-05 JP JP30307997A patent/JP4820956B2/en not_active Expired - Fee Related
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7201924B2 (en) * | 2001-09-07 | 2007-04-10 | Peter Grandics | Method for cancer therapy using herbal extracts |
| EP1539202A4 (en) * | 2002-08-23 | 2008-01-09 | Sterogene Bioseparations Inc | METHOD OF TREATING CANCER USING HERB EXTRACTS |
| CN104877037A (en) * | 2015-05-21 | 2015-09-02 | 北京电子科技职业学院 | Separation and purification method, products and application of Christia vespertilionis polysaccharides |
| US10233264B2 (en) * | 2016-05-04 | 2019-03-19 | South China Botanical Garden, Chinese Academy Of Sciences | Process for preparing (1→6)-α-D-glucan |
Also Published As
| Publication number | Publication date |
|---|---|
| JP4820956B2 (en) | 2011-11-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110437288B (en) | Sea cucumber fucoidin and preparation method and application thereof | |
| JPS62209101A (en) | Immuno-stimulative polysaccharides from cell culture of echinacea prupurea or echinacea angustifolia, its production and preparation containing the same | |
| CN110218264A (en) | A kind of Lyophyllum decastes granulose and its preparation method and application | |
| CN104892793B (en) | Phellinus igniarius mycelium polysaccharide, preparation method and its in antitumor application | |
| Yang et al. | Polysaccharides from traditional Asian food source and their antitumor activity | |
| KR20010050186A (en) | The hematopoietic, myeloid protecting, antitumor immune cells generating and radiosensitizing polysaccharide isolated from Panax ginseng | |
| CN109232760A (en) | Phellinus protect liver polysaccharide PPB-2 and preparation method thereof | |
| AU2018202402B2 (en) | Homogeneous polysaccharide with immunoregulation activity and preparation method thereof | |
| KR101949889B1 (en) | Method for preparing anticancer or immunactive polysaccharide from residues of immature citrus extract or immature citrus peel | |
| EP1560855B1 (en) | Polysaccharide of echinacea angustifolia | |
| CN104861085B (en) | Glucans of Chinese chestnut kernel α 1,6 and preparation method thereof and the application in antineoplastic | |
| JP4820956B2 (en) | Method for producing apple vinegar-derived antitumor polysaccharide and apple vinegar-derived antitumor polysaccharide obtained thereby | |
| JPS5945301A (en) | Polysaccharide and its preparation | |
| CN114195907B (en) | Low-molecular-weight spirulina polysaccharide and preparation method and application thereof | |
| KR19990081594A (en) | New Use of Polysaccharide Materials Isolated from Felinus Linteus | |
| JP2838862B2 (en) | Hypoglycemic agent | |
| WO1998027992A1 (en) | Antitumor active substances | |
| KR970011556B1 (en) | Purification Method of Longevity Mushroom Extract | |
| JP2838863B2 (en) | Hypoglycemic inhibitor | |
| JPH0379602A (en) | Polysaccarhide having immno- stimulation/anti-proliferation effect, its manufacture and drug containing said material | |
| JPH0314289B2 (en) | ||
| CN109400731A (en) | A kind of cold-water-soluble astragalus polyose and preparation method thereof and its extracorporeal anti-tumor application | |
| El-Badry et al. | Characterization and antitumor activity of polysaccharides from different fungal taxa in the Gharbiya governorate, Egypt. | |
| CN118165138A (en) | Edible fungus glucomannan and preparation method and anti-tumor application thereof | |
| JP4995440B2 (en) | Composition for preventing and / or treating tumor containing garlic treatment product |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070703 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20070918 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20071106 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20071210 |
|
| A911 | Transfer of reconsideration by examiner before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20080110 |
|
| A912 | Removal of reconsideration by examiner before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20080201 |
|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A712 Effective date: 20090514 |
|
| RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20100201 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20100201 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20110615 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20110813 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140916 Year of fee payment: 3 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313117 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |